We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 11-20 of 1,524

Court overturns C$125 million damages award based on extent of inadmissible hearsay evidence relied on by judge
  • Dentons
  • Canada
  • March 28 2017

In May 2016 the Federal Court of Appeal overturned a judgment for C$125 million in damages and sent the case back to the trial judge for

Federal Court grants injunction that allows infringing biologic drug to stay on the market
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

FCA holds FC erred by rejecting relevance of non-infringing alternatives
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • April 4 2017

Another judgment affirms that the non-infringing alternative (“NIA”) defence is relevant in the reduction of accounting of profits awards. In this

International Trade Compliance Update - September 2016
  • Baker McKenzie
  • United Kingdom, USA, Australia, Canada, European Union
  • September 7 2016

On 19 August 2016, the Russian Federation notified the WTO that it intends to initiate negotiations pursuant to Paragraph 1143 of the Working Party

Biosimilars in Canada: at a tipping point
  • Osler Hoskin & Harcourt LLP
  • Canada
  • May 24 2016

Biosimilars, or highly similar versions of innovative biologic medicines, have now been approved and marketed in developed countries for several

Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from

December 2016 International Trade Compliance
  • Baker McKenzie
  • OECD, United Kingdom, USA, Australia, Canada, European Union, Global
  • December 12 2016

On 29 November 2016, the WTO reported that most WTO members welcomed Ecuador’s efforts to lower its import surcharge rates and reduce the number of

Permanent injunction granted despite patentee not having a product that practiced the claims of the patent
  • Gowling WLG
  • Canada
  • June 18 2014

On May 22, 2014, the Federal Court of Canada issued an injunction curtailing Janssen Inc.’s marketing of its drug ustekinumab (STELARA) in ongoing

Tribunal Decides in Favour of Canada in NAFTA Arbitration Suit
  • Bereskin & Parr LLP
  • Canada
  • March 21 2017

The Government of Canada has prevailed in its NAFTA arbitration suit with Eli Lilly and Company “Lilly”. Lilly sued the sued the government as a

Tribunal dismisses Eli Lilly’s NAFTA challenge on promise utility doctrine
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • March 27 2017

As previously reported, Eli Lilly submitted claims to international arbitration under the North American Free Trade Agreement (NAFTA) seeking damages